Image Credit: University of Southern California (USC) Eye Institute Over the last two decades CIRM has supported research and helped advance potential treatments for macular degeneration, one of the leading causes of blindness. Early grants One of the earliest was a 2007 SEED grant to David Hinton, MD, of the University of Southern California (USC). … Continue reading The evolution of a CIRM-funded therapy for macular degeneration
Dry AMD
Luxa Biotechnology’s CIRM-funded Dry AMD Therapy Milestone
Credit: Shutterstock The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to a promising new treatment for dry age-related macular degeneration (AMD)—a leading cause of vision loss. The therapy is being developed by Luxa Biotechnology and supported in part by the California Institute for Regenerative Medicine (CIRM). What RMAT Designation Means RMAT designation … Continue reading Luxa Biotechnology’s CIRM-funded Dry AMD Therapy Milestone